Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Lauren E. Nye"'
Autor:
Shane R. Stecklein, Bruce F. Kimler, Rachel Yoder, Kelsey Schwensen, Joshua M. Staley, Qamar J. Khan, Anne P. O’Dea, Lauren E. Nye, Manana Elia, Jaimie Heldstab, Trisha Home, Stephen Hyter, Kamilla Isakova, Harsh B. Pathak, Andrew K. Godwin, Priyanka Sharma
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-8 (2023)
Abstract Triple-negative breast cancer (TNBC) patients with residual disease (RD) after neoadjuvant systemic therapy (NAST) are at high risk for recurrence. Biomarkers to risk-stratify patients with RD could help individualize adjuvant therapy and in
Externí odkaz:
https://doaj.org/article/00318f24d99f4b07bfee5dde9a0b9a2e
Autor:
Cory Bivona, Kevin Li, Priyanka Sharma, Jianghua He, Grace Martin, Andrew K Godwin, Anthony Rooney, Stephen Williamson, Gary Doolittle, Weijing Sun, Bruce F Kimler, Anne P O'Dea, Lauren E Nye, Joseph P McGuirk, Ziyan Pessetto, Lisa Haney, Nicole Balmaceda, Laura Mitchell, Karissa Finke, Maggie Nelson, Dinesh Pal Mudaranthakam, Natalie Streeter, Stephanie Lafaver, Jaimie Heldstab, Qamar J Khan
Publikováno v:
Cancer Research. 82:P4-10
Background: Infection with SARS-CoV-2 has led to a global pandemic and has significantly impacted the care of cancer patients. Breast cancer patients receiving active systemic therapy need protection against COVID19 but the efficacy of vaccines in th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2bffe47d2aba08b99634963be56dc78f
https://doi.org/10.1158/1538-7445.sabcs21-p4-10-03
https://doi.org/10.1158/1538-7445.sabcs21-p4-10-03
Autor:
Lauren E Nye, Jennifer R Klemp, Kandy R Powers, Anne P O'Dea, Amy L Kreutzjans, Trina Metheny, Teresa A Phillips, Susan E Carlson, Bruce F Kimler, Carol J Fabian
Publikováno v:
Cancer Research. 82:P2-11
Background: Nearly 10% of breast cancers (BC) are diagnosed in premenopausal woman under age 45 and of childbearing potential. Women considering future childbearing are typically excluded from BC prevention trials and are ineligible for standard of c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::98083f9657426997668dac9d81c7d8f3
https://doi.org/10.1158/1538-7445.sabcs21-p2-11-17
https://doi.org/10.1158/1538-7445.sabcs21-p2-11-17
Autor:
Priyanka Sharma, Shane R Stecklein, Bruce F Kimler, Rachel Yoder, Kelsey Schwensen, Joshua M Staley, Qamar J Khan, Anne P O'Dea, Lauren E Nye, Manana Elia, Jaimie Heldstab, Trisha Home, Stephen Hyter, Kamilla Isakova, Harsh B Pathak, Andrew K Godwin
Publikováno v:
Cancer Research. 82:P2-01
Introduction: Residual disease (RD) after neoadjuvant chemotherapy (NACT) is associated with high risk of recurrence in TNBC. RCB classification is prognostic in patients with RD. Recent studies show that post-NACT circulating cell-free tumor DNA (ct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d9c01093f423e0cde427d331c67310a7
https://doi.org/10.1158/1538-7445.sabcs21-p2-01-05
https://doi.org/10.1158/1538-7445.sabcs21-p2-01-05